Tennessee Attorney General Skrmetti and a bipartisan coalition are urging consumers to check their eligibility for compensation for certain generic drug purchases as the Attorneys General seek preliminary approval for a $39.1 million settlement with generic drug manufacturer Apotex over a conspiracy to inflate prices and limit competition.
Attorney General Skrmetti and the coalition previously announced the settlement in principle with Apotex last year along with a $10 million settlement with Heritage Pharmaceuticals. At the time of that announcement, the settlement with Apotex was conditioned on the signatures of all necessary states and territories. Those signatures have been obtained, and the coalition is filing the settlement today in the U.S. District Court for the District of Connecticut in Hartford.
The settlement agreements resolve allegations that both Apotex and Heritage engaged in widespread, long-running conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade regarding numerous generic prescription drugs. As part of the settlement agreements, both Apotex and Heritage have agreed to cooperate in the ongoing multistate litigations against 30 corporate defendants and 25 individual executives. Both companies have further agreed to a series of internal reforms to ensure fair competition and compliance with antitrust laws…